Get Red Pepper's email newsletter. Enter your email address to receive our latest articles, updates and news.

×

Held hostage by Big Pharma: a personal experience

Mike Marqusee looks at how drug firms can make huge profits from their state-enforced monopoly on an essential good

November 26, 2013
7 min read


Mike MarquseeMike Marqusee 1953–2015, wrote a regular column for Red Pepper, 'Contending for the Living', and authored a number of books on the politics of culture, on topics ranging from cricket to Bob Dylan.


  share     tweet  

In recent months, I’ve been taking a medication called Revlimid, given as a ‘late therapy’ for multiple myeloma. Since it looks like I may be Revlimid-dependent for a while, I decided to educate myself about the drug. As the chemistry is beyond me, I focussed my attention elsewhere.

The first thing I discovered was that Revlimid is phenomenally expensive.

A single 21-day cycle of treatment at the lowest dose of 5 mg daily costs the NHS £3,570. As the dose rises, so does the price, but not proportionally: for a single 21 day cycle at the high dose of 25 mg, it’s £4,318. The increment is small because the costs of actually manufacturing the drug are minimal. But whatever it is that we’re paying for, we’re paying for it through the nose: between £42,000 and £51,000 per patient for a year’s treatment. This is a treatment we need and to which we have a right. That does not, however, mean that its cost should be taken for granted.

Revlimid, it turns out, is a major profit generator for a medium-sized pharmaceutical company called Celgene, based in New Jersey. Though it directly employs only 4,000 people, Celgene’s 2012 revenues were $6.2 billion, up from $5.5 billion the previous year. After paying tax (at an effective rate of only 5%), profits on that revenue amounted to $1.6 billion, a 26% profit-to-sales ratio, high even by pharma industry standards.

Sales of Revlimid contributed more than $1 billion to Celgene’s revenues last year, making it by some way the company’s biggest cash cow. The Revlimid patent extends to 2027 and according to the company, ‘revenue is not near its potential peak’. (The drug has recently been approved for use in China.) Not surprisingly, Celgene’s NASDAQ listed share price has risen steadily, up 113% over the last year.

Celgene also makes the version of thalidomide used in the treatment of multiple myeloma as well as a new myeloma therapy called Pomalyst, licensed in the USA and currently under review by NICE.

Who knew so much money could be made out of multiple myeloma? It’s considered a rare disease, accounting for only one per cent of all cancers. Currently there are about 14,000 people in Britain and 75,000 in the USA living with multiple myeloma. Not a vast market but clearly a profitable one, though still only a sliver of the $1.1 trillion global pharmaceutical industry.

Like other pharmaceutical companies, Celgene claims its high prices are needed to sustain research and development. However, like other pharmaceutical companies, Celgene spends the majority of its revenue not on R&D, but on sales, marketing, lobbying, legal fees, acquisitions, plus the 26% dispersed in profits. In keeping with an industry-wide trend, revenues and profits have grown faster than investment in R&D.

Exclusive license

Celgene can charge exorbitantly for Revlimid because it owns an exclusive license to produce it. The formula itself is easy to replicate and if it were not for legal restraints, could be produced generically for a fraction of the cost. This multi-billion dollar business is built on a state-enforced monopoly of an essential good.

On examination, the rationale for that monopoly crumbles. Scientific research is cumulative and collective. The development of Revlimid was only possible because of a chain of advances in molecular biology and other disciplines. On what basis does the fruit of that process belong exclusively to Celgene’s shareholders?

In a revealing trend, pharmaceutical companies increasingly out-source core functions, including drug discovery itself. This reduces fixed costs but vitiates the neoliberal argument that innovation is inextricably tied to private ownership of the final product. It shows that innovation can be paid for and rewarded as a separate function, and that patent-holding exclusivity is not a necessary component of the process.

According to Big Pharma, their corporate model is the only way to advance research. Historically, however, medical advances have largely depended on public institutions (hospitals and universities); the corporate model is relatively recent. It is also a model compromised at its scientific core. The reliance on capitalist incentive for investment, as opposed to investment determined by public need, distorts the field as a whole. Increasingly, research is dictated by marketing. The aim is to produce a profitable drug; R&D priorities are set accordingly. As can be seen in the long-running resistance of Big Pharma to full publication of clinical trials data, the imperatives of competition put a brake on the sharing of information, which is the basis of scientific advance.

Patenting the sun

Jonas Salk, who discovered the first polio vaccine in the early 1950s, refused to take out a patent for the drug. Explaining his logic, he asked rhetorically, “Could you patent the sun?” He also noted that he had already been paid for his work on the drug through his regular salary as a university-based research scientist. (Not surprisingly, he was placed under surveillance by the FBI.)

Celgene has been criticised for its involvement in the American Legislative Exchange Council (ALEC), a body described by John Nichols in The Nation as a ‘collaboration between multinational corporations and conservative state legislators’. ALEC’s causes include reducing corporate regulation and taxation, privatising public services, tightening voter identification rules (making it harder for minorities, students and the poor to vote), minimizing environmental protection and promoting gun rights. It’s also zealous for ‘tougher’, longer sentencing, which directly benefits ALEC members like the Corrections Corporation of America and the GEO Group, two of the US’s largest for-profit prison companies.

ALEC also promotes ‘Stand-your-ground laws’ of the type used in Florida to justify the murder of Trayvon Martin. In response to that atrocity, activists announced a boycott of Coca-Cola because of its support for ALEC. Within hours, the company announced it was ending its relationship with the right-wing lobbying group. Others followed, including Wendy’s, Kraft Foods, McDonald’s, Apple, Procter & Gamble and even Wal-mart. But not Celgene, or indeeed GlaxoSmithKline, Bayer, Pfizer, or PhRMA (the pharmaceutical trade group). Alongside Big Pharma, tobacco, oil and energy giants also remain committed to ALEC.

Responding to criticisms of Celgene’s support for ALEC, Greg Chesmore, the company’s Senior Director of State Government Relations, declared last year that ‘participation in ALEC is consistent with Celgene’s vision, mission, values, and fully aligned with our commitment to improve the lives of patients worldwide’. In a perverse way, all that’s true.

In July 2012, The Guardian reported that ALEC had extended its operation to Britain, where it is lobbying against plain packaging of cigarettes. So it appears that some, admittedly small, part of the money the NHS hands over every year to Celgene ends up funding a campaign to undermine the health of people in Britain, adding to the NHS burden.

The NHS is spending a lot of money keeping me going. It was indeed the ‘cost-effectiveness’ of Revlimid that made NICE initially reluctant to approve it. After a vigorous public campaign by patient advocacy groups, NICE changed its position and Revlimid was made available on the NHS. I’m a beneficiary of this campaign, but so is Celgene. The clamour to save or prolong lives like mine undermined NICE’s bargaining position and strengthened Celgene’s. It’s a pattern seen in other controversies involving NICE, where health charities collaborate with pharmaceutical companies in pressing for rapid approval of new drugs.

Of course, the very idea of determining the “cost effectiveness” of a life-prolonging treatment is grotesque. What formula can possibly measure this kind of value? But anger at NICE is misdirected. The real problem is the extortionate prices demanded for life-prolonging drugs, and the real culprits are the pharmaceutical companies, who too often get away with making NICE the fall-guy for their rapacity.

In effect, companies like Celgene are hostage-takers: pay the ransom, they demand, or someone dies. The ruthlessness is breathtaking but is accepted as a corporate behavioural norm. What makes it more arch is that the hostage-taker claims to be on the side of the hostages. Though I’m one of those being held hostage by Big Pharma, I’ve experienced no trace of Stockholm Syndrome. On the contrary, I resent the way my illness, my vulnerability, has been exploited, used by a group of self-serving parasites to gouge the public purse.

www.mikemarqusee.com

Red Pepper is an independent, non-profit magazine that puts left politics and culture at the heart of its stories. We think publications should embrace the values of a movement that is unafraid to take a stand, radical yet not dogmatic, and focus on amplifying the voices of the people and activists that make up our movement. If you think so too, please support Red Pepper in continuing our work by becoming a subscriber today.
Why not try our new pay as you feel subscription? You decide how much to pay.
Share this article  
  share on facebook     share on twitter  

Mike MarquseeMike Marqusee 1953–2015, wrote a regular column for Red Pepper, 'Contending for the Living', and authored a number of books on the politics of culture, on topics ranging from cricket to Bob Dylan.


Contribute to Conter – the new cross-party platform linking Scottish socialists
Jonathan Rimmer, editor of Conter, says it’s time for a new non-sectarian space for Scottish anti-capitalists and invites you to take part

Editorial: Empire will eat itself
Ashish Ghadiali introduces the June/July issue of Red Pepper

Eddie Chambers: Black artists and the DIY aesthetic
Eddie Chambers, artist and art historian, speaks to Ashish Ghadiali about the cultural strategies that he, as founder of the Black Art Group, helped to define in the 1980s

Despite Erdogan, Turkey is still alive
With this year's referendum consolidating President Erdogan’s autocracy in Turkey, Nazim A argues that the way forward for democrats lies in a more radical approach

Red Pepper Race Section: open editorial meeting – 11 August in Leeds
The next open editorial meeting of the Red Pepper Race Section will take place between 3.30-5.30pm, Friday 11th August in Leeds.

Mogg-mentum? Thatcherite die-hard Jacob Rees-Mogg is no man of the people
Adam Peggs says Rees-Mogg is no joke – he is a living embodiment of Britain's repulsive ruling elite

Power to the renters: Turning the tide on our broken housing system
Heather Kennedy, from the Renters Power Project, argues it’s time to reject Thatcher’s dream of a 'property-owning democracy' and build renters' power instead

Your vote can help Corbyn supporters win these vital Labour Party positions
Left candidate Seema Chandwani speaks to Red Pepper ahead of ballot papers going out to all members for a crucial Labour committee

Join the Rolling Resistance to the frackers
Al Wilson invites you to take part in a month of anti-fracking action in Lancashire with Reclaim the Power

The Grenfell public inquiry must listen to the residents who have been ignored for so long
Councils handed housing over to obscure, unaccountable organisations, writes Anna Minton – now we must hear the voices they silenced

India: Modi’s ‘development model’ is built on violence and theft from the poorest
Development in India is at the expense of minorities and the poor, writes Gargi Battacharya

North Korea is just the start of potentially deadly tensions between the US and China
US-China relations have taken on a disturbing new dimension under Donald Trump, writes Dorothy Guerrero

The feminist army leading the fight against ISIS
Dilar Dirik salutes militant women-organised democracy in action in Rojava

France: The colonial republic
The roots of France’s ascendant racism lie as deep as the origins of the French republic itself, argues Yasser Louati

This is why it’s an important time to support Caroline Lucas
A vital voice of dissent in Parliament: Caroline Lucas explains why she is asking for your help

PLP committee elections: it seems like most Labour backbenchers still haven’t learned their lesson
Corbyn is riding high in the polls - so he can face down the secret malcontents among Labour MPs, writes Michael Calderbank

Going from a top BBC job to Tory spin chief should be banned – it’s that simple
This revolving door between the 'impartial' broadcaster and the Conservatives stinks, writes Louis Mendee – we need a different media

I read Gavin Barwell’s ‘marginal seat’ book and it was incredibly awkward
Gavin Barwell was mocked for writing a book called How to Win a Marginal Seat, then losing his. But what does the book itself reveal about Theresa May’s new top adviser? Matt Thompson reads it so you don’t have to

We can defeat this weak Tory government on the pay cap
With the government in chaos, this is our chance to lift the pay cap for everyone, writes Mark Serwotka, general secretary of public service workers’ union PCS

Corbyn supporters surge in Labour’s internal elections
A big rise in left nominations from constituency Labour parties suggests Corbynites are getting better organised, reports Michael Calderbank

Undercover policing – the need for a public inquiry for Scotland
Tilly Gifford, who exposed police efforts to recruit her as a paid informer, calls for the inquiry into undercover policing to extend to Scotland

Becoming a better ally: how to understand intersectionality
Intersectionality can provide the basis of our solidarity in this new age of empire, writes Peninah Wangari-Jones

The myth of the ‘white working class’ stops us seeing the working class as it really is
The right imagines a socially conservative working class while the left pines for the days of mass workplaces. Neither represent today's reality, argues Gargi Bhattacharyya

The government played the public for fools, and lost
The High Court has ruled that the government cannot veto local council investment decisions. This is a victory for local democracy and the BDS movement, and shows what can happen when we stand together, writes War on Want’s Ross Hemingway.

An ‘obscure’ party? I’m amazed at how little people in Britain know about the DUP
After the Tories' deal with the Democratic Unionists, Denis Burke asks why people in Britain weren't a bit more curious about Northern Ireland before now

The Tories’ deal with the DUP is outright bribery – but this government won’t last
Theresa May’s £1.5 billion bung to the DUP is the last nail in the coffin of the austerity myth, writes Louis Mendee

Brexit, Corbyn and beyond
Clarity of analysis can help the left avoid practical traps, argues Paul O'Connell

Paul Mason vs Progress: ‘Decide whether you want to be part of this party’ – full report
Broadcaster and Corbyn supporter Paul Mason tells the Blairites' annual conference some home truths

Contagion: how the crisis spread
Following on from his essay, How Empire Struck Back, Walden Bello speaks to TNI's Nick Buxton about how the financial crisis spread from the USA to Europe

How empire struck back
Walden Bello dissects the failure of Barack Obama's 'technocratic Keynesianism' and explains why this led to Donald Trump winning the US presidency


20